Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma.

Area of Science:

• Dermatology
• Oncology
• Hematology

Background:

• Primary cutaneous γ/δ T-cell lymphoma (PCGD-TCL) is aggressive, unlike subcutaneous panniculitis-like T-cell lymphoma (SPTCL).
• SPTCL, characterized by the α/β T-cell receptor phenotype, typically follows an indolent course with a favorable prognosis.
• Historically, PCGD-TCL and SPTCL were misclassified, leading to aggressive chemotherapy for both, despite SPTCL's less aggressive nature.

Purpose of the Study:

• To evaluate the efficacy of systemic corticosteroids as a treatment for SPTCL.
• To determine the clinical response rate of SPTCL to corticosteroid monotherapy.

Main Methods:

• Retrospective cross-sectional study design.
• Utilized a patient data repository spanning 13 years from two tertiary care university hospitals in Switzerland and Germany.
• Focused on patients diagnosed with SPTCL.

Main Results:

• Treatment with systemic corticosteroids resulted in a complete remission in 80% of SPTCL patients (4 out of 5).
• Demonstrated a high response rate to corticosteroid therapy in the studied SPTCL cohort.

Conclusions:

• Systemic corticosteroids represent a potentially excellent first-line monotherapy for SPTCL.
• Conservative treatment with corticosteroids may be a viable and effective option for managing SPTCL, avoiding more aggressive treatments.